Literature DB >> 25855675

Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.

Amalio Ruiz-Salas1, Jose Manuel García-Pinilla2, Fernando Cabrera-Bueno2, Julia Fernández-Pastor2, José Peña-Hernández2, Carmen Medina-Palomo2, Alberto Barrera-Cordero2, Eduardo De Teresa2, Javier Alzueta2.   

Abstract

AIMS: Hypertrophic cardiomyopathy is one of the main causes of sudden death in young people. Recent clinical practice guidelines include a risk prediction model for sudden death (HCM Risk-SCD), which facilitates the decision of whether to implant a defibrillator. The aim of our study was to ascertain the percentage of events in our series of primary prevention implantable cardioverter-defibrillator recipients with hypertrophic cardiomyopathy and whether HCM Risk-SCD predicts the onset of arrhythmic events. METHODS AND
RESULTS: This was an observational, retrospective cohort study, which included 48 primary prevention defibrillator recipient patients with HCM. We compiled their demographic and clinical characteristics, estimated 5-year risk using HCM Risk-SCD, and collected the documentation on arrhythmias during follow-up. The majority was male (66.7%) and mean age at implantation was 44.44 ± 14.46 years. Non-sustained ventricular tachycardia was the most prevalent risk factor (66.67%), followed by a family history of sudden death (47.92%). Mean HCM Risk-SCD was 6.15 ± 5.01%. HCM Risk-SCD was the only factor independently associated with the onset of ventricular tachyarrhythmia, above any other classic risk factor or association [odds ratio = 1.46 (95% confidence interval 1.051-2.013); P = 0.02]. None of the 11 patients estimated as low risk using HCM Risk-SCD suffered any appropriate events (P < 0.05).
CONCLUSIONS: During an average follow-up of 4 years, 16.67% presented appropriate events (4.16%/year). HCM Risk-SCD predicted the onset of events more suitably than classic risk factors. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Defibrillator; Hypertrophic cardiomyopathy; Sudden death

Mesh:

Year:  2015        PMID: 25855675     DOI: 10.1093/europace/euv079

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  10 in total

1.  MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction.

Authors:  Jing Xu; Baiyan Zhuang; Arlene Sirajuddin; Shuang Li; Jinghan Huang; Gang Yin; Lei Song; Yong Jiang; Shihua Zhao; Minjie Lu
Journal:  Radiology       Date:  2019-11-26       Impact factor: 11.105

2.  Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.

Authors:  Maxim Avanesov; Julia Münch; Julius Weinrich; Lennart Well; Dennis Säring; Christian Stehning; Enver Tahir; Sebastian Bohnen; Ulf K Radunski; Kai Muellerleile; Gerhard Adam; Monica Patten; Gunnar Lund
Journal:  Eur Radiol       Date:  2017-06-14       Impact factor: 5.315

3.  Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists.

Authors:  Arya Aminorroaya; Ali Vasheghani-Farahani; Farzad Masoudkabir; Pegah Roayaei
Journal:  J Interv Card Electrophysiol       Date:  2020-07-25       Impact factor: 1.900

Review 4.  Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.

Authors:  Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 5.  From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies.

Authors:  Nosheen Reza; Kiran Musunuru; Anjali Tiku Owens
Journal:  Curr Heart Fail Rep       Date:  2019-10

6.  The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.

Authors:  K Savostyanov; A Pushkov; I Zhanin; N Mazanova; S Trufanov; A Pakhomov; A Alexeeva; D Sladkov; A Asanov; A Fisenko
Journal:  Orphanet J Rare Dis       Date:  2022-05-16       Impact factor: 4.303

Review 7.  Implantable cardioverter-defibrillator in hypertrophic cardiomyopathy.

Authors:  Diego Jimenez Sanchez; Ignacio Fernández Lozano
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

8.  Study on Risk Factors for Death from Cardiomyopathy and Effectiveness of Health Information Management.

Authors:  Lei Wang; Shuping Zhang; Yan Wang; Jin Xuan; Yanli Han; Jianlin Ke
Journal:  J Healthc Eng       Date:  2021-12-07       Impact factor: 2.682

Review 9.  Update on hypertrophic cardiomyopathy and a guide to the guidelines.

Authors:  Srijita Sen-Chowdhry; Daniel Jacoby; James C Moon; William J McKenna
Journal:  Nat Rev Cardiol       Date:  2016-09-29       Impact factor: 32.419

10.  Prevention of sudden cardiac death in hypertrophic cardiomyopathy: Risk assessment using left atrial diameter predicted from left atrial volume.

Authors:  Helen Mills; Kiri Espersen; Rebecca Jurlander; Kasper Iversen; Henning Bundgaard; Anna Axelsson Raja
Journal:  Clin Cardiol       Date:  2020-03-07       Impact factor: 2.882

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.